Gilead's Phase 2 obeldesivir RSV trial terminated by sponsor; results posted
A 150-participant study testing obeldesivir for nonhospitalized adults with RSV was stopped early by Gilead, with results now posted to the registry.
Gilead Sciences reported one update this week on its obeldesivir RSV program.
- Obeldesivir (GS-5245), a Phase 2 oral antiviral, was tested against placebo in nonhospitalized adults with acute RSV infection under trial NCT06585150. The study was terminated by the sponsor, with the decision not due to any safety findings.1 It had enrolled 150 participants1 and aimed to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.1 Primary completion was recorded as 2025-05-08 (actual), with results first posted 2026-06-30 (actual).1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.